T. Rowe Price Associates
SOPH icon

T. Rowe Price Associates’s SOPHiA GENETICS SOPH Stock Holding History

T. Rowe Price Associates’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-958,500
Closed -$4.29M – 2911
2023
Q2 		$4.29M Sell
958,500
-69,062
-7% -$312K ﹤0.01% 1230
2023
Q1 		$5.11M Buy
1,027,562
+112,296
+12% +$364K ﹤0.01% 1179
2022
Q4 		$1.89M Sell
915,266
-40,240
-4% -$90.4K ﹤0.01% 1485
2022
Q3 		$2.51M Sell
955,506
-985,776
-51% -$3.45M ﹤0.01% 1372
2022
Q2 		$7.03M Sell
1,941,282
-378,458
-16% -$1.92M ﹤0.01% 1378
2022
Q1 		$17.9M Sell
2,319,740
-62,564
-3% -$703K ﹤0.01% 1256
2021
Q4 		$33.6M Buy
2,382,304
+23,863
+1% +$352K ﹤0.01% 1137
2021
Q3 		$41.3M Buy
+2,358,441
New +$41.5M ﹤0.01% 1086

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $4.69B AUM 24.1% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Associates's SOPH Position: Q3 2023 in Review

T. Rowe Price Associates sold out of SOPHiA GENETICS (SOPH) in Q3 2023, closing a stake of 958,500 shares — an estimated $4.29M sold.

T. Rowe Price Associates first reported a position in SOPH in Q3 2021 and held it in 8 quarters. The position peaked at $41.3M in Q3 2021. 32 funds tracked by Wall St. Rank hold SOPH as of Q3 2023.

  • T. Rowe Price Associates reported no remaining SOPHiA GENETICS position as of Q3 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 958,500 SOPHiA GENETICS shares in Q3 2023, an estimated $4.29M.
  • T. Rowe Price Associates first reported a position in SOPHiA GENETICS in Q3 2021 and held it in 8 quarters.
  • T. Rowe Price Associates's SOPHiA GENETICS position peaked at $41.3M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.